{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:30:37Z","timestamp":1792683037116,"version":"4.5.0"},"reference-count":29,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,26]]},"DOI":"10.1182\/bloodadvances.2025016748","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T17:23:59Z","timestamp":1750872239000},"page":"4190-4194","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Invasive fungal disease is rare in patients with relapsed\/refractory multiple myeloma treated with BCMA CAR T-cell therapy"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8093-5647","authenticated-orcid":false,"given":"Jessica S.","family":"Little","sequence":"first","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"},{"name":"2Division of Infectious Diseases, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica","family":"Medina Pena","sequence":"additional","affiliation":[{"name":"2Division of Infectious Diseases, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Bridget","family":"Kim","sequence":"additional","affiliation":[{"name":"3Department of Cellular Immunotherapy, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3623-7491","authenticated-orcid":false,"given":"Andrew J.","family":"Yee","sequence":"additional","affiliation":[{"name":"3Department of Cellular Immunotherapy, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Nadeem","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shonali","family":"Midha","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9369-4413","authenticated-orcid":false,"given":"Adam S.","family":"Sperling","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"},{"name":"4Division of Hematology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil C.","family":"Munshi","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noopur","family":"Raje","sequence":"additional","affiliation":[{"name":"3Department of Cellular Immunotherapy, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Frigault","sequence":"additional","affiliation":[{"name":"3Department of Cellular Immunotherapy, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5719-581X","authenticated-orcid":false,"given":"Diana D.","family":"Cirstea","sequence":"additional","affiliation":[{"name":"3Department of Cellular Immunotherapy, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4271-7443","authenticated-orcid":false,"given":"Sarah P.","family":"Hammond","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"},{"name":"3Department of Cellular Immunotherapy, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA"},{"name":"5Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"issue":"8","key":"2025082608220393900_bib1","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"2025082608220393900_bib2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2024025945","article-title":"Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma","volume":"145","author":"Sidana","year":"2025","journal-title":"Blood"},{"issue":"10 297","key":"2025082608220393900_bib3","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"The Lancet"},{"issue":"9","key":"2025082608220393900_bib4","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","article-title":"A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy","volume":"30","author":"Cordas Dos Santos","year":"2024","journal-title":"Nat Med"},{"issue":"8","key":"2025082608220393900_bib5","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/bloodadvances.2023011767","article-title":"Applying the EHA\/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality","volume":"8","author":"Rejeski","year":"2024","journal-title":"Blood Adv"},{"issue":"1","key":"2025082608220393900_bib6","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-023-01465-x","article-title":"The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma","volume":"16","author":"Rejeski","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2025082608220393900_bib7","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J"},{"issue":"10","key":"2025082608220393900_bib8","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1200\/JCO.22.02197","article-title":"Acknowledging infection risk in bispecific antibody trials in the treatment of multiple myeloma","volume":"41","author":"Cliff","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025082608220393900_bib9","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/S1473-3099(23)00377-8","article-title":"Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients","volume":"24","author":"Teh","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"2025082608220393900_bib10","doi-asserted-by":"crossref","first-page":"304.e1","DOI":"10.1016\/j.jtct.2022.03.005","article-title":"Pathogen-specific humoral immunity and infections in B cell maturation antigen-directed chimeric antigen receptor T cell therapy recipients with multiple myeloma","volume":"28","author":"Josyula","year":"2022","journal-title":"Transpl Cell Ther"},{"issue":"24","key":"2025082608220393900_bib11","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.1182\/bloodadvances.2022008320","article-title":"Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma","volume":"6","author":"Logue","year":"2022","journal-title":"Blood Adv"},{"issue":"Suppl 1","key":"2025082608220393900_bib12","doi-asserted-by":"crossref","first-page":"e14157","DOI":"10.1111\/tid.14157","article-title":"Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies","volume":"25","author":"Kampouri","year":"2023","journal-title":"Transpl Infect Dis"},{"issue":"3","key":"2025082608220393900_bib13","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.cmi.2024.11.008","article-title":"Timeline and outcomes of viral and fungal infections after chimeric antigen receptor T-cell therapy: a large database analysis","volume":"31","author":"Sassine","year":"2025","journal-title":"Clin Microbiol Infect"},{"issue":"18","key":"2025082608220393900_bib14","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1182\/bloodadvances.2023010524","article-title":"Respiratory infections predominate after day 100 following B-cell maturation antigen-directed CAR T-cell therapy","volume":"7","author":"Little","year":"2023","journal-title":"Blood Adv"},{"issue":"23","key":"2025082608220393900_bib15","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1182\/bloodadvances.2021004896","article-title":"Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days","volume":"5","author":"Mikkilineni","year":"2021","journal-title":"Blood Adv"},{"issue":"7","key":"2025082608220393900_bib16","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1182\/bloodadvances.2020004079","article-title":"Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy","volume":"6","author":"Thiruvengadam","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"2025082608220393900_bib17","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41408-024-01043-5","article-title":"Comparison of infectious complications with BCMA-directed therapies in multiple myeloma","volume":"14","author":"Nath","year":"2024","journal-title":"Blood Cancer J"},{"issue":"6","key":"2025082608220393900_bib18","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1182\/bloodadvances.2024015008","article-title":"Characteristics of infections after BCMA-directed CAR T-cell therapy for multiple myeloma: a real-world analysis","volume":"9","author":"Richardson","year":"2025","journal-title":"Blood Adv"},{"issue":"6","key":"2025082608220393900_bib19","doi-asserted-by":"crossref","first-page":"ofae133","DOI":"10.1093\/ofid\/ofae133","article-title":"The burden of invasive fungal disease following chimeric antigen receptor T-cell therapy and strategies for prevention","volume":"11","author":"Little","year":"2024","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"2025082608220393900_bib20","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jtct.2024.12.013","article-title":"The bottom line of CAR-T fungal risk: low incidence, high stakes and the need for individualised antifungal prophylaxis","volume":"31","author":"Reynolds","year":"2025","journal-title":"Transpl Cell Ther"},{"issue":"6","key":"2025082608220393900_bib21","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"16","key":"2025082608220393900_bib22","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1182\/bloodadvances.2022007474","article-title":"Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma","volume":"6","author":"Little","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"2025082608220393900_bib23","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"7","key":"2025082608220393900_bib24","doi-asserted-by":"crossref","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"1","key":"2025082608220393900_bib25","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jtct.2024.10.010","article-title":"Shift from widespread to tailored antifungal prophylaxis in lymphoma patients treated with CD19 CAR T cell therapy: results from a large retrospective cohort","volume":"31","author":"Melica","year":"2025","journal-title":"Transpl Cell Ther"},{"issue":"3","key":"2025082608220393900_bib26","doi-asserted-by":"crossref","first-page":"ofae082","DOI":"10.1093\/ofid\/ofae082","article-title":"Modeling invasive aspergillosis risk for the application of prophylaxis strategies","volume":"11","author":"Young","year":"2024","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"2025082608220393900_bib27","doi-asserted-by":"crossref","first-page":"e004475","DOI":"10.1136\/jitc-2021-004475","article-title":"The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL","volume":"10","author":"Rejeski","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025082608220393900_bib28","doi-asserted-by":"crossref","first-page":"104134","DOI":"10.1016\/j.critrevonc.2023.104134","article-title":"Infections in haematology patients treated with CAR-T therapies: a systematic review and meta-analysis","volume":"192","author":"Reynolds","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"2025082608220393900_bib29","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/cid\/ciz1127","article-title":"Invasive mold infections after chimeric antigen receptor-modified T-cell therapy: a case series, review of the literature, and implications for prophylaxis","volume":"71","author":"Haidar","year":"2020","journal-title":"Clin Infect Dis"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/16\/4190\/2406777\/blooda_adv-2025-016748-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/16\/4190\/2406777\/blooda_adv-2025-016748-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T12:22:12Z","timestamp":1756210932000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/16\/4190\/537934\/Invasive-fungal-disease-is-rare-in-patients-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":29,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2025,8,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016748","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8,26]]},"published":{"date-parts":[[2025,8,14]]}}}